Skip to main content

Table 3 Safety assessment of the GMA in the five major special situation sub-groups with the incidence and 95% CI

From: Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study

  AEADEFP
Patients/sub-groupTotaln(%)95% CIn(%)95% CIn(%)95% CI
Patients eligible for safety analysis43750(11.4) 11(2.5) 71(16.2) 
Patients who received GMA retreatment13113(9.9)0.054–0.1643(2.3)0.008–0.07611(8.4)0.043–0.145
Patients on multiple immunosuppressant medications12519(15.2)0.094–0.2275(4.0)0.009–0.08023(18.4)0.120–0.263
Elderly patients (≥65 years)12514(11.2)0.063–0.1810(0.0)0.000–0.02922(17.6)0.114–0.254
Patients with anaemia (haemoglobin < 10 g/dL)10519(18.1)0.113–0.2684(3.8)0.016–0.10822(21.0)0.136–0.300
Paediatric/adolescent patients (≤18 years)5310(18.9)0.094–0.3203(5.7)0.021–0.18211(20.8)0.108–0.341
  1. GMA granulocyte and monocyte adsorptive apheresis, CI confidence interval, AE adverse event, ADE adverse device effect, FP feasibility problem